Guardian Partners Inc. Invests $2.54 Million in Illumina, Inc. (NASDAQ:ILMN)

Guardian Partners Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,161 shares of the life sciences company's stock, valued at approximately $2,537,000.

Other hedge funds have also recently bought and sold shares of the company. WCM Investment Management LLC boosted its stake in shares of Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after buying an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock valued at $454,617,000 after acquiring an additional 27,618 shares in the last quarter. Geode Capital Management LLC boosted its stake in Illumina by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock valued at $354,933,000 after acquiring an additional 48,018 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock worth $282,735,000 after acquiring an additional 625,245 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Illumina by 4.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company's stock worth $164,334,000 after purchasing an additional 54,319 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Remove Ads

Illumina Stock Down 0.7 %

Shares of ILMN stock traded down $0.55 on Thursday, reaching $82.28. 1,812,730 shares of the company's stock traded hands, compared to its average volume of 2,110,750. The business's 50 day moving average price is $103.93 and its two-hundred day moving average price is $127.08. The company has a market capitalization of $13.03 billion, a P/E ratio of -10.71, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 12-month low of $80.18 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of several research analyst reports. Barclays reaffirmed an "underweight" rating on shares of Illumina in a research report on Tuesday, March 11th. Royal Bank of Canada reduced their target price on Illumina from $247.00 to $128.00 and set an "outperform" rating on the stock in a report on Wednesday, March 12th. Canaccord Genuity Group lowered their price target on Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a report on Tuesday, March 11th. Robert W. Baird decreased their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. Finally, Stephens reiterated an "overweight" rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.